The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment

For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as wel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jin-Woo Kim, Su-Young Kim
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/94e901fc212c42a2bfbcb2265d38a2d7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!